Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BIO-TECHNE CORPORATION

(TECH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BIO-TECHNE CORPORATION : Ex-dividend day for

11/10/2021 EST

A dividend is removed today from Bio-Techne Corporation's share.



ę Factset 2021
All news about BIO-TECHNE CORPORATION
01/18BIO-TECHNE ANNOUNCES COMMERCIAL RELEASE OF HIGH SENSITIVITY FLUORESCENT DETECTION STELL..
PR
01/18Bio-Techne Corporation Announces Commercial Release of High Sensitivity Fluorescent Det..
CI
01/17Bio-techne to host conference call on february 1, 2022 to announce second quarter 2022 ..
PR
01/13Akoya Biosciences Says it is Making its PhenoCycler-Fusion Spatial Biology System Comme..
MT
01/12BIO TECHNE : Corporate Presentation – January 2022
PU
01/07Bio-techne announces updated presentation time at the j.p. morgan healthcare conference
PR
01/05Akoya Biosciences, Bio-Techne Enter Partnership to Develop Automated System for Tissue ..
MT
01/05Akoya Biosciences and Bio-Techne Partner to Deliver Automated Spatial Multiomics Workfl..
AQ
01/05Akoya Biosciences and Bio-Techne Partners to Deliver Automated Spatial Multiomics Workf..
CI
01/03Bio-techne to present at the j.p. morgan healthcare conference
PR
More news
Analyst Recommendations on BIO-TECHNE CORPORATION
More recommendations
Financials (USD)
Sales 2022 1 090 M - -
Net income 2022 245 M - -
Net cash 2022 180 M - -
P/E ratio 2022 61,7x
Yield 2022 0,35%
Capitalization 14 425 M 14 425 M -
EV / Sales 2022 13,1x
EV / Sales 2023 11,4x
Nbr of Employees 2 600
Free-Float 99,4%
Chart BIO-TECHNE CORPORATION
Duration : Period :
Bio-Techne Corporation Technical Analysis Chart | TECH | US09073M1045 | MarketScreener
Technical analysis trends BIO-TECHNE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 367,10 $
Average target price 528,82 $
Spread / Average Target 44,1%
EPS Revisions
Managers and Directors
Charles R. Kummeth President, Chief Executive Officer & Director
James T. Hippel CFO & Principal Accounting Officer
Robert V. Baumgartner Chairman
Robert Monroe Chief Medical Officer
Brenda Swierenga Furlow Secretary & Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
BIO-TECHNE CORPORATION-29.04%14 425
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508